NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Other Current Assets and Liabilities, Net
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Other Current Assets and Liabilities, Net of $17.20 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet · last filed 2023-02-09
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets and liabilities, net for the quarter ending 2020-03-31 was $4.10M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets and liabilities, net for the quarter ending 2019-03-31 was -$3.30M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets and liabilities, net for fiscal 2022 was $17.20M, a 86.96% increase from fiscal 2021.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets and liabilities, net for fiscal 2021 was $9.20M, a 61.02% decline from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets and liabilities, net for fiscal 2020 was $23.60M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets and liabilities, net for fiscal 2019 was -$16.80M.
| Period end | Increase (Decrease) in Other Current Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Current Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Current Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|
| 2022-12-31 | $17.20M 10-K · filed 2023-02-09 | ||
| 2021-12-31 | $9.20M 10-K · filed 2023-02-09 | ||
| 2020-12-31 | $23.60M 10-K · filed 2023-02-09 | ||
| 2020-03-31 | $4.10M 10-Q · filed 2020-05-06 | ||
| 2019-12-31 | -$16.80M 10-K · filed 2022-02-11 | -$21.88M 10-K · filed 2020-02-07 | |
| 2019-03-31 | -$3.30M 10-Q · filed 2020-05-06 | ||
| 2018-12-31 | -$2.70M 10-K · filed 2021-02-05 | $6.04M 10-K · filed 2019-02-08 | |
| 2017-12-31 | $3.99M 10-K · filed 2020-02-07 | ||
| 2016-12-31 | -$1.38M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |